Home  »  Finance   »  Navidea Biopharmaceuticals Inc. (NAVB): Honey Is W...

Navidea Biopharmaceuticals Inc. (NAVB): Honey Is Worth The Money

Navidea Biopharmaceuticals Inc. (AMEX:NAVB) concluded the trading at $0.12 on Thursday, September 14 with a rise of 3.45% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $0.12 with its price kept floating in the range of $0.11 and $0.14 on the day. Considering stock’s 52-week price range provides that NAVB hit a high price of $0.35 and saw its price falling to a low level of $0.06 during that period. Over a period of past 1-month, stock came adding 65.98% in its value.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


With its current market valuation of $12.00 million. Analysts are in estimates of $0 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to $0 for 2023 with estimates of that growing to $0 in next year.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review NAVB stock’s current outlook then short term indicators are assigning it an average of 50% Sell, while medium term indicators are categorizing the stock at an average of 50% Sell. Long term indicators are suggesting an average of 50% Sell for it.

Digging deeper we become aware of the PEG ratio of the NAVB stock which is currently positioned at 0. It further provides that stock’s current price level is 35.15% away from its 20-day simple moving average and is 31.34% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 66.40 while volatility remained at 18.60% over the past week which changes to 16.74% when measuring it over the past month. Beta is valued at 1.49, while measure of average true range or ATR is currently at 0.01.

Having a second look at Navidea Biopharmaceuticals Inc. (AMEX:NAVB) provides that stock’s average daily trading volume for 3 months was 7.06 million, while it jumped to 5.57 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 99.83 million.

The percentage of outstanding shares held by the insiders is 26.30% while it is 4.70% for the institutional holders. The figures also indicate that as of Aug 14, 2023, number of stock’s short shares was 0.53 million which implies a short ratio of 0.17. This shows down a 0.54% of Short Interest in company’s outstanding shares on the day. In August the standing of shares short improved as it was 1.25 million in the previous month. Subtraction of -42.86% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.